Search

KR-102962213-B1 - Cosmetic composition for skin anti-inflammatory and skin soothing

KR102962213B1KR 102962213 B1KR102962213 B1KR 102962213B1KR-102962213-B1

Abstract

The present disclosure relates to a cosmetic composition for skin anti-inflammation and skin soothing purposes. Specifically, the cosmetic composition of the present disclosure can achieve anti-inflammatory effects and skin soothing effects by controlling the expression of mediators related to inflammatory skin diseases.

Inventors

  • 황정환
  • 박부만
  • 정유라
  • 박묘현
  • 신혜성

Assignees

  • (주)네오팜

Dates

Publication Date
20260513
Application Date
20241014

Claims (12)

  1. A cosmetic composition for skin anti-inflammatory and skin soothing, comprising a compound represented by the following chemical formula 1 and a compound represented by chemical formula 2. [Chemical Formula 1] [Chemical Formula 2] (The above R1 and R3 are nonyl, The above R2 is methyl, and The above L1 to L3 are methylene)
  2. delete
  3. delete
  4. delete
  5. In paragraph 1, A cosmetic composition for skin anti-inflammatory and skin soothing, wherein the composition comprises 0.5 to 2 moles of a compound represented by Formula 2 for every 1 mole of a compound represented by Formula 1.
  6. In paragraph 1, A cosmetic composition for skin anti-inflammatory and skin soothing, comprising 0.001 to 1 weight percent of the compound represented by Chemical Formula 1 and the compound represented by Chemical Formula 2 based on the total composition.
  7. In paragraph 1, The above cosmetic composition is formulated as a softening lotion, an astringent lotion, a nourishing lotion, an eye cream, a nourishing cream, a massage cream, a cleansing cream, a cleansing foam, a cleansing water, a powder, an essence, or a pack, and is a cosmetic composition for skin anti-inflammatory and skin soothing.
  8. A pharmaceutical composition for the prevention or treatment of dermatitis comprising a compound represented by the following chemical formula 1 and a compound represented by chemical formula 2. [Chemical Formula 1] [Chemical Formula 2] (The above R1 and R3 are nonyl, The above R2 is methyl, and The above L1 to L3 are methylene)
  9. delete
  10. delete
  11. In paragraph 8, The above pharmaceutical composition is a pharmaceutical composition for the prevention or treatment of dermatitis that inhibits one or more inflammatory factors selected from TNF-α, IL-6, and IL-8.
  12. In paragraph 8, A pharmaceutical composition for the prevention or treatment of dermatitis, wherein the above-mentioned dermatitis is atopic dermatitis or psoriasis.

Description

Cosmetic composition for skin anti-inflammatory and skin soothing The present invention relates to a cosmetic composition for skin anti-inflammation and skin soothing, and more specifically, to a cosmetic composition for skin anti-inflammation and soothing that has an anti-inflammatory effect by controlling the expression of mediators related to inflammatory skin diseases. Skin inflammation occurs when cells are damaged by various causes, including biological factors such as bacteria and viruses, physical factors such as mechanical irritation, heat, radiation, and electricity, or chemical substances. During this process, substances such as histamine and kinin are released, causing blood vessels to dilate, capillary permeability to increase, and macrophages to accumulate at the site of inflammation. As a result, blood flow increases and edema appears in the inflamed area, while immune cells and antibodies migrate to induce pain and fever. This reaction is one of the defense mechanisms designed to prevent damage to biological tissues. Skin inflammatory responses are initiated as a biological reaction to protect the skin from external stimuli or damage, involving various immune cells and inflammation-inducing cytokines. These cytokines include interleukins, chemokines, tumor necrosis factor (TNF), and interferons, while several growth factors play important roles in regulating inflammation and tissue regeneration. Examples include insulin-like growth factor (IGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF). Currently, synthetic drugs such as ibuprofen, antihistamines, steroids, and immunosuppressants are used to treat inflammatory skin diseases, but these drugs only provide temporary symptom relief or can cause hypersensitivity reactions and worsening of the immune system. In addition, anti-inflammatory cosmetic compositions using natural extracts have been attempted, but their actual application has been limited due to skin irritation, discoloration, and solubility issues. Against this backdrop, research was conducted on specific compounds that inhibit the activity of inflammation-inducing cytokines, and as a result, it was discovered that certain alcohol or amino acid-derived compounds have low cytotoxicity and allergy-inducing potential and are effective in inhibiting the production of inflammation-inducing cytokines such as IL-8 and IL-17. Based on this, the present invention aims to provide an anti-inflammatory cosmetic composition that alleviates inflammation and soothes the skin. Figure 1 shows the mRNA expression levels of a) TNF-alpha b) IL-6, and c) IL-8 analyzed by qPCR when the compositions of the examples and comparative examples of the present disclosure were treated to human keratinocytes. FIG. 2 shows the results of IHC staining treatment (a) and the ratio of stained areas (b) according to the expression of IL-6, after treating an artificial skin model (EpiDermFT™) with the compositions of the examples and comparative examples of the present disclosure. FIG. 3 shows the results of IHC staining treatment (a) and the ratio of stained areas (b) according to the expression of IL-8, after treating an artificial skin model (EpiDermFT™) with the compositions of the examples and comparative examples of the present disclosure. The present invention will be described in detail below. Unless otherwise defined, terms used in this specification should be interpreted as generally understood by those skilled in the art. The drawings and embodiments of this specification are intended to enable those skilled in the art to easily understand and practice the present invention; therefore, details that may obscure the essence of the invention may be omitted from the drawings and embodiments, and the present invention is not limited to the drawings and embodiments. The singular form used in this specification may be intended to include the plural form unless specifically indicated otherwise in the context. Furthermore, the numerical range used in this invention includes lower and upper limits and all values within the range, increments logically derived from the form and width of the defined range, all of the specified values, and all possible combinations of upper and lower limits of the numerical range defined in different forms. Unless otherwise specifically defined in the specification of this invention, values outside the numerical range that may occur due to experimental error or rounding are also included in the defined numerical range. In this specification, terms such as "include," "have," and "have" mean that the features or components described in the specification are present, and unless specifically limited, this does not preclude the possibility that one or more other features or components may be added. The term "inflammation" used in the present invention refers to a phenomenon that occurs for a series of defensive purposes to minimize